Risk of subarachnoid hemorrhage and early case fatality associated with outpatient antithrombotic drug use

Stroke

Volumn 44, Issue 9, 2013, Pages 2422-2426

  Garbe, Edeltraut ^a,b   Kreisel, Stefan H ^c   Behr, Sigrid ^a  

^a LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

^b UNIVERSITY OF BREMEN   (Germany)

^c EVANGELISCHES KRANKENHAUS   (Germany)

Author keywords

Anticoagulant; Coumarin; Phenprocoumon; Platelet aggregation inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; TICLOPIDINE; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG FATALITY; DRUG USE; FEMALE; GROUPS BY AGE; HEALTH INSURANCE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; RISK FACTOR; SUBARACHNOID HEMORRHAGE;

ANTICOAGULANT; COUMARIN; PHENPROCOUMON; PLATELET AGGREGATION INHIBITORS;

ADULT; AGED; ANTICOAGULANTS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; REGISTRIES; RISK FACTORS; SEX FACTORS; SUBARACHNOID HEMORRHAGE;

EID: 84884501149     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.000811     Document Type: Article

References (27)

1. de Rooij NK, Linn FH, van der Plas JA, Algra A, Rinkel GJ. Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. J Neurol Neurosurg Psychiatry. 2007;78:1365-1372.
2. Feigin VL, Rinkel GJ, Lawes CM, Algra A, Bennett DA, van Gijn J, et al. Risk factors for subarachnoid hemorrhage: an updated systematic review of epidemiological studies. Stroke. 2005;36:2773-2780.
3. Johnston SC, Selvin S, Gress DR. The burden, trends, and demographics of mortality from subarachnoid hemorrhage. Neurology. 1998;50:1413-1418.
4. van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet. 2007;369:306-318.
5. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol. 2009;8:355-369.
6. Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, Rinkel GJ. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol. 2009;8:635-642.
7. Greebe P, Rinkel GJ, Hop JW, Visser-Meily JM, Algra A. Functional outcome and quality of life 5 and 12.5 years after aneurysmal subarachnoid haemorrhage. J Neurol. 2010;257:2059-2064.
8. Kissela BM, Sauerbeck L, Woo D, Khoury J, Carrozzella J, Pancioli A, et al. Subarachnoid hemorrhage: a preventable disease with a heritable component. Stroke. 2002;33:1321-1326.
9. Rinkel GJ, Djibuti M, Algra A, van Gijn J. Prevalence and risk of rupture of intracranial aneurysms: a systematic review. Stroke. 1998;29:251-256.
10. Ruigrok YM, Buskens E, Rinkel GJ. Attributable risk of common and rare determinants of subarachnoid hemorrhage. Stroke. 2001;32:1173-1175.
11. Hein L, Schwabe U. Antikoagulantien und Thrombozytenaggregationshemmer. In: Schwabe U, Paffrath D, eds. Arzneiverordnungsreport. Heidelberg: Springer Medizin Verlag; 2007:425-438.
12. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005;44:1227-1246.
13. Behr S, Schill W, Pigeot I. Does additional confounder information alter the estimated risk of bleeding associated with phenprocoumon use-results of a two-phase study. Pharmacoepidemiol Drug Saf. 2012;21:535-545.
14. Jobski K, Behr S, Garbe E. Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case-control study in a large population-based German database. Eur J Clin Pharmacol. 2011;67:941-951.
15. Behr S, Andersohn F, Garbe E. Risk of intracerebral hemorrhage associated with phenprocoumon exposure: a nested case-control study in a large population-based German database. Pharmacoepidemiol Drug Saf. 2010;19:722-730.
16. Schink T, Garbe E. Representativity of dispensations of non-steroidal antiinflammatory drugs (NSAIDs) in the German Pharmacoepidemiological Research Database. Pharmacoepidemiol Drug Saf. 2010;19:S294. Abstract.
17. Rothman KJ, Greenland S, Lash TL. Case-Control Studies. In: Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology. 3 rd. Philadelphia, PA: Lippincott Williams & Wilkens; 2008:111-127.
18. Daly LE. Confidence limits made easy: interval estimation using a substitution method. Am J Epidemiol. 1998;147:783-790.
19. EUROSTAT-Europe in Figures. Eurostat yearbook 2008. Available at: URL: http://epp.eurostat.ec.europa.eu. Accessed: April 3, 2013.
20. International Agency for Research on Cancer. Statistical Methods in Cancer Research - Volume II - The Design and Analysis of Cohort Studies. IARC Scientific Publications No. 82. Available at: URL:http://www.iarc.fr/en/ publications/pdfs-online/stat/sp82/SP82.pdf. 1987. Accessed: April 3, 2013.
21. Risselada R, Straatman H, van Kooten F, Dippel DW, van der Lugt A, Niessen WJ, et al. Platelet aggregation inhibitors, vitamin K antagonists and risk of subarachnoid hemorrhage. J Thromb Haemost. 2011;9:517-523.
22. Olsen M, Johansen MB, Christensen S, Sørensen HT. Use of vitamin K antagonists and risk of subarachnoid haemorrhage: a population-based case-control study. Eur J Intern Med. 2010;21:297-300.
23. Schmidt M, Johansen MB, Lash TL, Christiansen CF, Christensen S, Sørensen HT. Antiplatelet drugs and risk of subarachnoid hemorrhage: a population-based case-control study. J Thromb Haemost. 2010;8:1468-1474.
24. Risselada R, Lingsma HF, Bauer-Mehren A, Friedrich CM, Molyneux AJ, Kerr RS, et al. Prediction of 60 day case-fatality after aneurysmal subarachnoid haemorrhage: results from the International Subarachnoid Aneurysm Trial (ISAT). Eur J Epidemiol. 2010;25:261-266.
25. Pigeot I, Ahrens W. Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations. Pharmacoepidemiol Drug Saf. 2008;17:215-223.
26. Schink T, Garbe E. Assessment of the representativity of in-patient hospital diagnoses in the German Pharmacoepidemiological Research Database. Pharmacoepidemiol Drug Saf. 2010;19:S178-S179. Abstract.
27. de Rooij NK, Rinkel GJ, Dankbaar JW, Frijns CJ. Delayed cerebral ischemia after subarachnoid hemorrhage: a systematic review of clinical, laboratory, and radiological predictors. Stroke. 2013;44:43-54.